Eli Lilly Shares Reach Record High Amid Regulatory and Market Developments
Shares of Eli Lilly (NYSE: LLY) reached a new all-time high following positive regulatory developments in Europe for its cancer drug Jaypirca, as well as the launch of Medicare coverage for its obesity medications Zepbound and Foundayo. These milestones are expected to significantly expand patient access and market potential.
Topics: Eli Lilly Foundayo Jaypirca Medicare GLP-1 Bridge program Zepbound